DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
CUDC-101 is an investigational drug.
There have been 12 clinical trials for CUDC-101. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Rahul Aggarwal.
There are two hundred and fifty-three US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for CUDC-101
|The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.||Aarhus University Hospital||Phase 1|
|CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer||National Cancer Institute (NCI)||Phase 2|
|Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for CUDC-101
Top clinical trial sponsors for CUDC-101
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CUDC-101||⤷ Try it Free||Histone deacetylase inhibitors and methods for use thereof||REACTION BIOLOGY CORP. (Malvern, PA)||⤷ Try it Free|
|CUDC-101||⤷ Try it Free||Anti-CS1 antibodies and antibody drug conjugates||AbbVie Biotherapeutics Inc. (Redwood City, CA)||⤷ Try it Free|
|CUDC-101||⤷ Try it Free||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||⤷ Try it Free|
|CUDC-101||⤷ Try it Free||Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections||EMORY UNIVERSITY (Atlanta, GA)||⤷ Try it Free|
|CUDC-101||⤷ Try it Free||Methods and compositions for treating antiprogestin-resistant cancers||FUNDACION SALES (Capital Federal, AR)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CUDC-101||World Intellectual Property Organization (WIPO)||WO2017030892||2035-08-14||⤷ Try it Free|
|CUDC-101||Australia||AU2015339012||2034-10-31||⤷ Try it Free|
|CUDC-101||Brazil||BR112017008945||2034-10-31||⤷ Try it Free|
|CUDC-101||Canada||CA2966005||2034-10-31||⤷ Try it Free|
|CUDC-101||European Patent Office||EP3212668||2034-10-31||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|